Rhabdomyosarcoma (RMS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Rhabdomyosarcoma (RMS) is the most common soft-tissue sarcoma in children. RMS can occur anywhere in the body, including the head and neck, genitourinary organs, extremities, and abdomen. Although still debated, evidence suggests that RMS arises from the mesenchymal cell lineage, which is typically fated to become skeletal muscle tissue. RMS is traditionally classified into two major histological subtypes, embryonal RMS (ERMS) and alveolar RMS (ARMS), of which 60–70% of cases are ERMS and 20–30% are ARMS. 80% of ARMS cases are defined by a chromosomal translocation between PAX3 or PAX7 and FOXO1 genes; these translocations result in fusion genes that largely drive oncogenic activity. The other 20% of ARMS cases are similar to ERMS in terms of clinical outcomes and the pattern of somatic mutations. Despite the clinical significance of RMS, the underlying etiologies remain the environmental and genetic factors individually contribute to this malignancy.

·       Approximately 50% of all pediatric soft-tissue sarcoma diagnoses are Rhabdomyosarcoma with an incidence of approximately 4.71 per million children and adolescents less than 20 years of age in the United States.

 

Thelansis’s “Rhabdomyosarcoma (RMS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Rhabdomyosarcoma (RMS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Rhabdomyosarcoma (RMS) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Rhabdomyosarcoma (RMS) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Rhabdomyosarcoma (RMS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Rhabdomyosarcoma (RMS), Rhabdomyosarcoma (RMS) market outlook, Rhabdomyosarcoma (RMS) competitive landscape, Rhabdomyosarcoma (RMS) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)

 

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033